Also trades as: LABS.TO (TSX) · $vol 0M
MEDIF OTC
MediPharm Labs Corp.
1W: +1.0%
1M: -3.6%
3M: +1.4%
YTD: +0.2%
1Y: -8.4%
3Y: -10.3%
5Y: -76.7%
$0.05
-0.00 (-3.40%)
Weekly Expected Move ±7.9%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$42M
+26.9% ▲
5Y CAGR: -20.1%
Gross Profit
$13M
+118.7% ▲
5Y CAGR: -21.5%
Operating Income
-$11M
+40.8% ▲
Net Income
-$11M
+18.3% ▲
EPS (Diluted)
$-0.03
+27.2% ▲
EBITDA
-$8M
+28.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $36M | $22M | $22M | $33M | $42M |
| YoY Growth | -72.1% | -39.7% | +1.9% | +49.5% | +26.9% |
| Cost of Revenue | $80M | $37M | $24M | $27M | $29M |
| Gross Profit | -$44M | -$15M | -$2M | $6M | $13M |
| Gross Margin | -122.1% | -70.2% | -8.7% | 17.7% | 30.5% |
| R&D Expenses | $2M | $1M | $1M | $209K | $235K |
| SG&A Expenses | $29M | $23M | $25M | $25M | $23M |
| Operating Expenses | $27M | $28M | $27M | $24M | $24M |
| Operating Income | -$73M | -$49M | -$30M | -$18M | -$11M |
| Operating Margin | -201.5% | -225.3% | -133.5% | -55.2% | -25.8% |
| Interest Expense | $8M | $11M | $31K | $365K | $576K |
| Income Before Tax | -$72M | -$55M | -$30M | -$13M | -$11M |
| Tax Expense | -$5M | $113K | -$6K | -$276K | $0 |
| Net Income | -$67M | -$55M | -$30M | -$13M | -$11M |
| Net Margin | -186.4% | -252.4% | -135.6% | -39.6% | -25.5% |
| EPS (Diluted) | $-0.48 | $-0.22 | $-0.11 | $-0.04 | $-0.03 |
| EBITDA | -$53M | -$39M | -$25M | -$10M | -$8M |
| Shares Outstanding | 139M | 250M | 277M | 363M | 408M |